Molecule to Market: Inside the outsourcing space

Meet the Supply Chain Wizard

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Evren Ozkaya is the Founder & CEO of Supply Chain Wizard and SCW.AI.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Evren, covering:

 

• The job offer that pulled him away from the McKinsey fast track and into the pharma industry
• Getting hands on experience at Sandoz, delivering real impact before spotting the opportunity to found his own business
• The moment that triggered the shift from consulting to technology, and the rapid build out of a software platform
• The decision to spin out the Digital Factory into a standalone company and raise $10m in Series A funding
• The importance of simplicity and creating a single source of truth on the factory floor
• Why the industry must move towards interconnected, systems thinking rather than isolated point to point solutions
• Why strong networks remain a hidden but powerful advantage in the life sciences sector

 

Evren Ozkaya, Ph.D. is the Founder & CEO of Supply Chain Wizard (a management consulting firm) and SCW.AI (a technology platform company), helping Pharma manufacturers establish and execute cost-effective and scalable digital transformation programs across manufacturing and supply chain domains by leveraging the state-of-the-art technology.

 

As a former management consultant at McKinsey & Company and a supply chain executive at Sandoz/Novartis, Dr. Ozkaya led various business transformation programs in over 100 companies in industries such as pharmaceuticals, consumer goods, industrial, logistics and private equity.

 

Evren Ozkaya received his Ph.D. in Industrial and Systems Engineering from Georgia Institute of Technology with his award-winning thesis on Demand Management in Global Supply Chains. Dr. Ozkaya currently serves as the Chair of the Advisory Board at the School of Industrial and Systems Engineering at Georgia Tech, besides his other advisory board roles at Rutgers Business School and Seton Hall University.

 

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Building a Canadian CDMO from grad school

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Lisa Studnicki Hunt, Ph.D, Co-Founder and Board Member, GL CHEMTEC.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Lisa, covering:

 

• How her passion for problem solving led her to cofound a CDMO straight out of grad school
• How, without an established industry network, she focused on developing her core skill set and immersing herself in a different culture
• Figuring things out day by day, while pursuing opportunities aligned with the company’s long term vision
• Positioning the business as “innovation experts” to differentiate in a competitive and fragmented CRO and CDMO market
• How the pandemic accelerated demand and growth, ultimately leading to a well timed private equity deal
• The “misbehaving of the market” over the last few years, and how a Canadian CDMO is positioned amid geopolitical shifts involving the US and China

 

Lisa co-founded GL CHEMTEC INTERNATIONAL in 2002 and has played a key role in growing the organization across both operations and commercial functions for more than two decades.  She also now serves on several boards and is passionate about philanthropy and supporting non-profit organizations.

 

Lisa began her academic journey with a degree in Natural Sciences from John Abbott College. She went on to earn a Bachelor of Science with Honours, with a minor in French, and a Master of Science in Chemistry from the University of Toronto. She later completed her Doctor of Philosophy in Organic Polymer Chemistry at Friedrich Schiller University in Jena, Germany.

 

Lisa has authored several scientific publications and holds multiple patents. Alongside her scientific credentials, Lisa has continued to build her commercial and business expertise. She earned her Professional Sales Designation from the Canadian Professional Sales Association in 2008, completed the E2: Entrepreneur’s Edge course at Wilfrid Laurier University in 2009, attended Harvard Business School in 2015 under the guidance of renowned professor Clayton Christensen, and completed the Marketing Innovation course at MIT Sloan School of Management in 2017.

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

From Big Pharma to Biotech CEO

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Rachel Sha, CEO at Terrestrial Bio.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with Rachel, covering:

• Navigating the Genzyme Sanofi acquisition and building a leadership career on the other side of the transaction
• Being in the right place at the right time to pursue entrepreneurship, and the steep learning curve of stepping into a biotech CEO role
• The decision to adopt a dual strategy, partnering with biopharma on a platform technology while also advancing internal programs
• Leading a $50M Series C raise in a challenging funding environment and evolving the company’s identity
• The real world trade offs between building manufacturing capabilities in house versus outsourcing to CDMOs

Rachel Sha is the CEO at Terrestrial, a company focused on transforming the delivery of next generation therapies with its microarray skin patch that provides a patient friendly experience that is injection free and without the hassle of cold chain.  Prior to Terrestrial, she was an Operating Partner at Engine Ventures, a venture fund spun-out of MIT that invests in Tough Tech companies primarily in the Boston area.  She advised companies and worked with the investment team in exploring investment themes, opportunities, and programming.  Before her time in venture, she spent seventeen years at Genzyme and Sanofi where she held leadership positions in business development, strategy, and commercial.  Her last role at the firm was the Global Vice President of Digital Strategy, Partnering and Governance at Sanofi where she led global strategy, business development, and governance of digital programs to transform Sanofi and healthcare.

 

She has long been a supporter of developing women entrepreneurs and has supported organizations like Mass Next Gen and Springboard Enterprises.  She was recognized by the Boston Business Journal in the 2025 class of Women Who Lead in Life Sciences.  Rachel holds a BS from Massachusetts Institute of Technology in Chemistry and an MBA from Harvard Business School.

 

Please note: Vaxess Technologies is now Terrestrial (Terrestrial Bio, Inc.). This change reflects a brand evolution and is not part of a merger or acquisition. There has been no change in control or operations. All contracts, relationships and business activities continue uninterrupted under our new name.

 

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

From Lab to Boardroom at Sartorius

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with René, covering:

 

• How a lucky break brought him to Sartorius over 20 years ago, and what has changed and stayed the same over that time
• His journey from scientist to senior leader, and the evolution of biologics he has witnessed along the way
• The pace of innovation in bioprocessing, and how he thinks about speed, efficiency and flexibility
• Why innovation continues regardless of market cycles, through both boom and correction periods
• His perspective on the current biotech market reset and why it represents a healthy correction
• Despite building a €3.5bn powerhouse, how Sartorius has maintained a relentless focus on customers

 

René Fáber, born in 1975, has been Head of Bioprocess Solutions Division and Member of the Executive Board of Sartorius AG since 2019. In the same year, he became a Member of the Board of Directors of Sartorius Stedim Biotech S.A.; in 2023 he was appointed as CEO of the company. René Fáber studied chemistry in Bratislava, Slovakia, and earned his Ph.D. in polymer chemistry from the Technical University of Munich in Germany. He joined Sartorius in 2002, where he initially worked as a scientist on membrane modification. As Vice President, he held various management positions in R&D, Marketing for Filtration and Fermentation Technologies, as well as in Key Account Management. In his most recent position, he was responsible for the Product Development unit of the Bioprocess Solutions Division.

 

 

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

 

CDMO Live Europe: State of Contract Manufacturing 2026

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

 

• Kaan-Fabian Kekec, Partner Simon Kucher
• Kurt Nielson, President, Longview Leader
• Melanie Wamsler, External Network Strategy Lead, Takeda
• Rocco Paracchini, Vice President, Morpho

 

Your host, Raman Sehgal, discusses the state of contract manufacturing with his guests live from CDMO Live Europe 2026. The event was hosted by PharmaSource and Molecule to Market,

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Codexis at TIDES - Stereochemistry in RNA Manufacturing: Signal or Noise?

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

 

• Fred Fleitz, SVP, CMC and Development Chemistry, Arrowhead Pharmaceuticals
• Jason Costigan, Head of CMC, Corsera Health
• Alison Moore, CEO and President, Codexis, Inc.
• Muthu Kandasamy, VP of Medicinal Chemistry, Wave Life Sciences 

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his guests live from TIDES 2026. The event was hosted by Codexis and Molecule to Market,

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Navigating global supply chains at Big Pharma

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Daniel Hurni, Supply Chain Enterprise Capability Lead at Roche.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dan, covering:

 

• Why working all over the world was a key competent in building his confidence, and his understanding of people and perspectives from different cultures.
• The value of doing an MBA as a technician, and the need to master yourself and becoming the boss of yourself before leading others.
• A behind the scenes peek of CDMO sourcing and selection at small and a big pharma across different modalities.... and the importance of relationship building.
• Taking on a global supply chain lead at big pharma, and the job of navigating risk... and why you can only plan so much.
• How he's excited by, and thinking about AI with respect to supply chain, and why he will only apply it where it makes sense.
• Why listening, empathy, mentorship and networking are vital for survival and growth in a big pharma company.
• Top tips for large and specialist CDMOs.

 

With over 20 years of experience driving operational transformation in the life sciences sector, Daniel has established a reputation for optimizing end-to-end supply chains and navigating the complexities of the global pharma and biotech landscape. Throughout his career, he has successfully led high-stakes initiatives—ranging from aseptic Tech Transfers for sterile drug products to large-scale M&A integrations—consistently delivering cost reductions and scalable, patient-centric solutions within complex matrix environments. In small and large pharmaceutical companies.

 

Daniel specializes in bridging the gap between digital innovation and physical operations, leveraging AI, data integration, and advanced analytics to enhance S&OP and network design. Beyond his technical leadership in manufacturing and supplier management, he is a seasoned change management architect, adept at aligning functional priorities with enterprise strategy to drive operational agility. Daniel is also a frequent collaborator and thought leader who focuses on mentoring cross-functional teams and influencing stakeholders at all levels to build the intelligent, resilient supply chains of the future.

 

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Bora Live Panel - The Voice of the Customer

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

• Jennifer Chadwick, Founder and Principal at Jennifer Chadwick Consulting
• Firelli Alonso, Founder / Principal Consultant at ConsultFi Biologics LLC
• Umar Hayat, Founder, CEO at Accanito Inc

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his guests live from Bora Nexus 2026. The event was hosted by Bora Pharmaceuticals and Molecule to Market,

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

The Making of a CGT CDMO Builder

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Steve Favaloro, Chairman and CEO of Genezen.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Steve, covering:

• His deep passion for operations, and how early lessons in hard work and customer service shaped his leadership
• Learning from Mark Bamforth and the entrepreneurial journey at Brammer Bio, culminating in a $1.7bn exit to Thermo Fisher
• Why gaining exposure to every seat at the table was critical in preparing him for the CEO role
• Building Genezen with a focus on strong values, hiring the right people and investing in differentiated capabilities
• How the cell and gene therapy market has evolved over the past decade, and why he remains optimistic about the future of curative medicines
• Why things inevitably go sideways in innovative drug development, and the importance of being prepared to navigate it

Steve Favaloro is an experienced biotech executive, board member, and investor. He is currently Chairman and CEO of Genezen, a best-in-class gene and cell therapy CDMO with specialized expertise in viral vector manufacturing. Steve joined Genezen in 2023 and has built up a team of almost 300 employees, supporting gene and cell therapy innovators from early-stage, growth-oriented biotechs to established industry leaders. He is an executive advisor at Ampersand Capital Partners, a leading healthcare investor, and serves on the board of Biologos. He also serves on the board of advisors of Life Science Cares Boston.

Prior to Genezen, Steve was CFO at Arbor Biotech, a next-generation gene editing therapeutic company. Steve also served as CFO at Arranta Bio, a leading CDMO for mRNA, from its founding in 2019 to its successful exit to Recipharm in February 2022. 

Prior to this, Steve was a finance leader and ultimately CFO at Brammer Bio, where he oversaw a period of rapid expansion and capital deployment from 2016 to 2019 – leading up to its successful sale to Thermo Fisher Scientific in May 2019 for $1.7B. Before joining Brammer, Steve held finance roles of increasing responsibility at MilliporeSigma, Merck KGaA, and Bruker Corporation. Steve received his MBA and Master of Science from the Carroll School of Management at Boston College. Steve also received his Bachelor of Arts degree in Economics from Boston College.

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Inside the mind of the CMO outsourcer

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Felipe Furiati, Senior Director, External Supply Operations at Grünenthal.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Felipe, covering:

 

• Why he stepped away from big pharma to pursue an MBA in the US and transition into top tier management consulting, broadening his global perspective
• The pace and intensity of his time at Bain, and how it expanded his problem solving toolkit across industries
• The challenges, risks and opportunities involved in acquiring products and integrating supply chains
• How he approaches identifying, selecting and managing CDMO partners, and why product characteristics play a critical role
• Building and maintaining a CMO and CDMO network, and the key criteria he uses to assess and source new projects
• What strong vendor relationships really look like, why not every CDMO can be a strategic partner, and where CMOs can improve

 

Felipe currently works in External Supply Operations at Grünenthal, a mid-sized pharma organization with a vision of a world free of pain. He is an experienced professional in pharma strategy and operations, with a focus on external supply chain management across both pre launch and commercial products.

 

Originally from Brazil, Felipe has lived in Ireland and the United States, and is now based in Italy. His experience in the pharmaceutical industry is complemented by time in management consulting, where he gained exposure to a range of sectors including CPG and healthcare services.

 

Outside of work, Felipe is a mid of the pack endurance triathlete and enjoys spending time outdoors.

 

 

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!